NCI/CTEP 7998: A Phase I Study of ABT-888 in Combination with Cyclophosphamide in Solid Tumors or Non-Hodgkins Lymphoma

Print this page

NCI/CTEP 7998: A Phase I Study of ABT-888 in Combination with Cyclophosphamide in Solid Tumors or Non-Hodgkins Lymphoma

The main purpose of this study is to determine what is the best dose of ABT-888, a drug that prevents proteins from repairing DNA, in combination with cyclophosphamide, a chemotherapy drug that is commonly used to treat many types of cancer. Another goal of this study is to characterize the toxicities of combining ABT-888 and cyclophosphamide. In addition, the pharmacokinetics, or levels of each drug, will be assessed in the blood to evaluate how cyclophosphamide might alter the amount of ABT-888 that is eliminated from the blood.

Protocol Number050803
Principal InvestigatorAntoinette Tan
PhasePhase I
ScopeLocal
Applicable Disease SitesNon-Hodgkin's Lymphoma
Any Site
Therapies InvolvedChemotherapy multiple agents systemic
Drugs InvolvedDOXORUBICIN
CYCLOPHOSPHAMIDE
Participating InstitutionsRutgers Cancer Institute of New Jersey

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@umdnj.edu.